Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06209476 · ClinicalTrials.gov registry record
Clinical Investigation on Assessing the Repeatability and Reproducibility of Central and Peripheral Refractive Error
A clinical trial, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- 30
- Enrollment target
NCT06209476: Completed study, sponsored by Johnson & Johnson Vision Care.
NCT06209476 is a clinical trial that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06209476 has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This is a unilateral, non-interventional study. Each subject will be unilaterally measured with the WAM-5500 autorefractor by 3 testers. All measurements will be made on the right eye only.
Primary Outcome
Central (on-axis) cycloplegic auto-refraction will be measured to evaluate the intra-visit repeatability, inter-visit repeatability, and reproducibility of central refractive error measurements with the Grand Seiko WAM-5500.
Interventions
- DIAGNOSTIC_TEST Experimental
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2024-02-05 |
What the finished NCT06209476 record still lists
NCT06209476 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Experimental is the first listed.
NCT06209476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06209476 about?
NCT06209476 is a clinical study titled "Clinical Investigation on Assessing the Repeatability and Reproducibility of Central and Peripheral Refractive Error". This is a unilateral, non-interventional study. Each subject will be unilaterally measured with the WAM-5500 autorefractor by 3 testers. All measurements will be made on the right eye only.
What is the current status of trial NCT06209476?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2024-01-16. Estimated completion is 2024-02-05.
What interventions are being tested in trial NCT06209476?
The interventions under investigation include: Experimental (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06209476?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI